HeartBeam Inc. Receives FDA Clearance for Innovative Cable-Free ECG System

HeartBeam Inc. (NASDAQ: BEAT) has reached a significant milestone with the FDA 510(k) clearance of its innovative ECG system, a compact, cable-free device designed for arrhythmia detection. This clearance not only validates the system’s safety and efficacy but also paves the way for HeartBeam to revolutionize remote cardiac care by enabling patients to record and share ECGs from anywhere.

The device, which is about the size of a credit card, allows patients to use an app-guided system to record a 30-second ECG. This recording is then automatically uploaded to the cloud for physician review, facilitating timely and informed medical decisions. The company’s upcoming Early Access Program aims to involve early adopters and healthcare providers in the initial phase before the system’s broader market release.

This regulatory achievement is a stepping stone for HeartBeam’s future innovations, including the development of a 12-lead ECG synthesis, AI-based arrhythmia detection, and remote heart attack risk scoring. These advancements are part of HeartBeam’s broader vision to transform cardiac care by providing continuous, predictive insights outside traditional clinical settings, thereby improving patient outcomes and accessibility to care.

For more details on HeartBeam’s breakthrough, visit https://ibn.fm/go8CI.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is HeartBeam Inc. Receives FDA Clearance for Innovative Cable-Free ECG System.